Keyphrases
Celecoxib
100%
Adenocarcinoma Cells
100%
Prostate Carcinoma
100%
Rat Prostate
100%
Antitumor Properties
100%
Prostate Cancer
33%
Dose Effect
33%
Wistar Rats
33%
Pyrazole Ring
33%
PC-3M
33%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
16%
Induced Apoptosis
16%
Tumor
16%
Selenium
16%
Prostate Cancer Cells
16%
B-cell Lymphoma 2 (Bcl-2)
16%
Standard-of-care Chemotherapies
16%
Prostate Tumor
16%
Hypoxia-inducible factor-1α (HIF-1α)
16%
Antitumor Effect
16%
IC50
16%
Cyclooxygenase-2
16%
Cell-derived
16%
Two-level
16%
AKT1
16%
Tumor Weight
16%
Apoptotic Activity
16%
Subcutaneous Tumor
16%
Sulfonamide Antibiotics
16%
COX-2 Activity
16%
COX-2 Inhibitors
16%
Selenium Derivatives
16%
Hormone-sensitive Prostate Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Celecoxib
100%
Prostate Adenocarcinoma
100%
Prostate Cancer
50%
Selenium Compound
33%
Lobund Wistar Rat
33%
Pyrazole
33%
Chemotherapy
16%
Sulfonamide
16%
COX-2 Inhibitor
16%
Castration Resistant Prostate Cancer
16%
Prostate Tumor
16%
IC50
16%
Neoplasm
16%
Protein Kinase B
16%
Immunology and Microbiology
Lobund Wistar Rat
100%
In Vitro
100%
Cancer Cell
50%
Bcl-2
50%
IC50
50%
Programmed Cell Death
50%
Chemistry
Antitumor
100%
Celecoxib
100%
Selenium
33%
Pyrazole
33%
IC50
16%
Sulfonamide
16%
Biochemistry, Genetics and Molecular Biology
Celecoxib
100%
Lobund Wistar Rat
33%
Cancer Cell
16%
IC50
16%
Bcl-2
16%
COX-2 Inhibitor
16%
Protein Kinase B
16%
Sulfonamide
16%
Programmed Cell Death
16%
Neuroscience
Celecoxib
100%
In Vitro
33%
Pyrazole
33%
Bcl-2
16%
Protein Kinase B
16%
COX-2 Inhibitor
16%
Sulfonamide
16%
Programmed Cell Death
16%